Source: International Congress 2014 – Biology and pathology of thoracic tumours
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. W. Kim, C. D. Yeo, J. M. Lee, H. H. Kang, S. H. Lee (Seoul, Republic Of Korea). Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model. Eur Respir J 2014; 44: Suppl. 58, 2697

Member's Comments

No comment yet.

Related content which might interest you: Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Improving NLST criteria for lung cancer screening Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Lung cancer and lung tuberculosis: Our results of treatment in the combined lung disease Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Cox-2 inhibitors in the treatment of small cell lung cancer patients Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Accelerated lung function decline increases the risk of lung cancer Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Evaluation of lung cancer patients with distant organ metastasis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Lung cancer in women: Is it different? Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Assessment of nutritional status in patients with primary lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Approach to hypersensitivity reactions to chemotherapeutics in patients with lung cancer Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 The role of HIF-1 pathway in non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016